Abstract:HomeCirculationVol. 142, No. 7Crosstalk Between the Heart and Cancer Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessEditorialPDF/EPUBCrosstalk Between the Heart and CancerBeyond Drug Toxicity Javid Moslehi, MD Qing Zhang, PhD Kathryn J. MoorePhD Javid MoslehiJavid Moslehi Javid Moslehi, MD, Cardio-Oncology Program, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, TN 37232. Email E-mail Address: [email protected] Department of Medicine, Divisions of Cardiovascular Medicine and Oncology, Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, TN (J.M.). , Qing ZhangQing Zhang https://orcid.org/0000-0002-6595-8995 Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Q.Z.). , Kathryn J. MooreKathryn J. Moore Kathryn J. Moore, PhD, Leon H. Charney Division of Cardiology, NYU Cardiovascular Research Center, New York University Grossman School of Medicine, New York, NY 10016. Email E-mail Address: [email protected] Department of Medicine, Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, NY (K.L.M.). Originally published17 Aug 2020https://doi.org/10.1161/CIRCULATIONAHA.120.048655Circulation. 2020;142:684–687This article is a commentary on the followingEarly Cardiac Remodeling Promotes Tumor Growth and MetastasisArticle, see p 670Cardio-oncology has blossomed as a new clinical and research subspecialty in cardiovascular medicine owing to the explosion of novel cancer therapies, which have dramatically changed the natural course of cancer but are also associated with cardiovascular and metabolic sequelae.1 The intersection of cardiology and oncology is increasingly recognized to extend beyond toxic effects of cancer or cancer therapies on the cardiovascular system. Common risk factors, including genetic ones, can predispose to both cancer and heart disease.2,3 Furthermore, recent data also suggest that heart failure and cardiac ischemic insults may potentiate cancer progression (Figure).4 In this issue of Circulation, Avraham and colleagues5 demonstrate that early hypertrophic cardiac remodeling, in the absence of heart failure, enhances tumor growth and metastasis, further highlighting the crosstalk between cardiovascular disease and cancer.Download figureDownload PowerPointFigure. Cardio-oncology. The intersection between cancer and cardiovascular disease extends beyond cancer and cancer treatment effects on the cardiovascular and cardiometabolic systems. There is a growing appreciation of common risk factors that predispose patients to both cancer and cardiovascular disease. Emerging data also suggest the concept of reverse cardio-oncology whereby heart disease potentiates cancer.Cancer and heart disease represent major public health burdens and are the 2 most common causes of death in the world. Although often viewed as distinct disease entities, cardiovascular disease and cancer often occur in the same individual. Cardiovascular risk factors such as tobacco use, diabetes mellitus, and hyperlipidemia have been associated with an increase in cancer risk.1,3 Genetic entities such as clonal hematopoiesis of indeterminate potential—somatic mutations in hematopoietic stem cells previously recognized as a major risk factor for hematologic malignancies—have emerged as potent risk factors for cardiovascular events.2 Fundamental biological mechanisms such as chronic inflammation that contribute to both conditions have been proposed to drive these associations. However, demonstrating potential links between existing cardiovascular disease and subsequent malignancy can be challenging clinically. For example, lead-time bias, whereby diagnosis time of cancer is advanced by screening, may occur among patients with heart failure as a result of more frequent visits to a health care provider.6Laboratory platforms provide a more objective and biologically dissectible means of addressing the hypothesis that cardiac injury potentiates tumor. In 2018, in groundbreaking experiments, Meijers and colleagues4 used an elegant genetic mouse model prone to precancerous intestinal tumors. Subjecting these mice to myocardial infarction resulted in an increased number and size of intestinal polyps. Heterotopic heart transplantation, whereby an infarcted or sham-operated heart was transplanted into a recipient mouse, also led to increased tumor number, volume, and proliferation, ruling out hemodynamic impairment as a simple explanation. A number of candidate secreted proteins were identified that were elevated in mice subjected to myocardial infarction, as well as patients with heart failure, which promoted tumorigenesis in vitro. The new study by Avraham and colleagues5 supports cardiac remodeling as an acute pathologic stressor that accelerates cancer by the secretion of protumorigenic factors.Avraham and colleagues5 used transverse aortic constriction (TAC) in mice, which simulates pressure overload–induced cardiac hypertrophy, to investigate whether pathologic cardiac remodeling can alter cancer growth and progression. TAC was found to enhance tumor growth in 2 mouse syngeneic tumor models: a breast orthotopic cancer model (mouse mammary tumor virus–polyomavirus middle T antigen) and a lung cancer model (Lewis lung carcinoma). TAC resulted in increased volume of tumor implants, with higher numbers of proliferating tumor cells, as well as enhanced metastatic colonization compared with tumors grown in mice after either a sham surgery or no operation. Temporal delay in tumor implantation after TAC, corresponding to greater cardiac hypertrophy, resulted in larger growth of tumors, suggesting a correlation between hypertrophied remodeling and tumor growth. To determine whether the host immune system played a role in TAC-associated increased tumor growth, experiments were repeated in immunodeficient NOD/SCID mice, which lack T and B lymphocytes, and have reduced natural killer cell function; however, the differential effects of tumor growth after TAC persisted, excluding a significant role for the adaptive immune system. It is notable that sera derived from TAC-operated mice enhanced cancer cell proliferation in vitro, suggesting the role of a secreted molecule in mediating tumor growth.Transcriptomic profiling of the hearts from TAC-operated mice identified a number of candidate factors upregulated in cardiac tissue that were previously recognized to be protumorigenic, including connective tissue growth factor and periostin.7 The authors showed that connective tissue growth factor and periostin were also increased in the sera of TAC-operated mice, compared with mice that underwent sham surgery, independent of cancer. Periostin is a nonstructural matricellular protein that regulates key aspects of tumor biology, including proliferation, invasion, and dissemination to premetastatic niches in distant organs.8 Exogenous addition of periostin was sufficient to increase polyomavirus middle T antigen and Lewis lung carcinoma cell proliferation in vitro, and depletion of periostin from the sera of TAC mice abrogated its proliferative effects on polyomavirus middle T antigen cells. Whereas these in vitro studies showed that periostin is a necessary component in sera from TAC-operated mice to drive cancer cell replication, it is unclear whether the concentration used represents the physiological condition in vivo after the TAC procedure. Furthermore, in vitro tumor proliferation assays cannot recapitulate the complex tumor microenvironment, which includes both immune and stromal–vascular cells, and no studies of periostin inhibition in vivo were performed to validate its causal role. Future studies will be needed to investigate whether periostin, either by itself or by collaborating with other secreted factors, promotes cardiac remodeling–associated tumorigenesis in vivo.Whereas TAC is frequently used in the laboratory to study adverse cardiac remodeling on pressure overload, there is considerable variability in severity and time course to heart failure, depending on mouse strain, sex, follow-up time, and severity of the surgical constriction. Initially developed by Rockman and colleagues9 as an in vivo murine model of myocardial cell hypertrophy, the model progresses to ventricular dilatation and heart failure. Detailed characterization of the myocardium after TAC has revealed induction of chemokines and cytokines and limited inflammation, with subsequent fibrosis.10 In the present study, the cardiac hypertrophy clearly developed but remodeling did not include subsequent ventricular dilatation. In addition, both the innate and adaptive immune system contribute to pathology in heart failure models, which may promote cross-disease communication.11,12 Although NOD/SCID mice were used in the present study to exclude the potential role of the immune system in cardiac remodeling–mediated tumor growth, these mice still maintain low natural killer cell activity and myeloid cell function, which may have contributed to the observed cancer phenotype.13 Because myeloid cells have important roles in tumorigenesis in both the mouse mammary tumor virus–polyomavirus middle T antigen and Lewis lung carcinoma orthotopic models used, further studies will be needed to investigate such a possibility. Work by one of our groups (Dr Moore) shows that an incident myocardial infarction accelerates breast cancer outgrowth in mice, by epigenetic modification of monocytes in the bone marrow.14 Additional testing of the effects of TAC in genetically engineered mouse models of cancer are needed to assess whether early cardiac remodeling affects transformation (de novo cancer formation) or merely the growth and metastasis of existing tumors.To address the human disease relevance of the meticulous mouse experiments, the authors retrospectively assessed echocardiographic data of >80 000 patients, nearly 5000 of whom had a clinical diagnosis of aortic stenosis, and tried to find correlations with subsequent diagnosis of nonhematologic malignancies between those with or without aortic stenosis. Whereas the crude hazard ratio suggested an increased incidence rate of malignancy in patients with moderate or severe aortic stenosis compared with those with no aortic stenosis, once corrected for other confounders, such as smoking or diabetes mellitus, this correlation only held true in the younger population (40–60 years old). These data are suggestive, but they are preliminary, with the added caveat that TAC is at best a very exaggerated form of aortic stenosis. Prospective clinical studies using cardiac imaging will be needed to address systematically whether cardiac remodeling potentiates the risk of cancer in humans. Still, the authors' results add to the growing dimension of reverse cardio-oncology.15 In 2020, the field of cardio-oncology continues to evolve, with growing appreciation of interaction between cardiovascular disease and cancer.DisclosuresDr Moslehi has served on advisory boards for Pfizer, Novartis, Bristol-Myers Squibb, Deciphera, Audentes Pharmaceuticals, Nektar, Ipsen, Takeda, Myokardia, AstraZeneca, TripleGene/Precisgen, Regeneron GlaxoSmithKline, Boston Biomedical, ImmunoCore, Janssen, and Myovant. Dr Zhang is a Cancer Prevention and Research Institute of Texas Scholar.Sources of FundingDr Moslehi is supported by the US National Institutes of Health through grant no. R01 HL141466. Dr Zhang is supported by the Cancer Prevention and Research Institute of Texas through grant no. RR190058 and the National Cancer Institute through grant no. R01CA211732. Dr Moore is supported by the National Institutes of Health through grant nos. R35HL135799 and P01HL131478.Footnoteshttps://www.ahajournals.org/journal/circThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Javid Moslehi, MD, Cardio-Oncology Program, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, TN 37232. Email javid.[email protected]eduKathryn J. Moore, PhD, Leon H. Charney Division of Cardiology, NYU Cardiovascular Research Center, New York University Grossman School of Medicine, New York, NY 10016. Email kathryn.[email protected]orgReferences1. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies.N Engl J Med. 2016; 375:1457–1467. doi: 10.1056/NEJMra1100265CrossrefMedlineGoogle Scholar2. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, et al.. Age-related clonal hematopoiesis associated with adverse outcomes.N Engl J Med. 2014; 371:2488–2498. doi: 10.1056/NEJMoa1408617CrossrefMedlineGoogle Scholar3. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer.Cardiovasc Res. 2019; 115:844–853. doi: 10.1093/cvr/cvz035CrossrefMedlineGoogle Scholar4. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, et al.. Heart failure stimulates tumor growth by circulating factors.Circulation. 2018; 138:678–691. doi: 10.1161/CIRCULATIONAHA.117.030816LinkGoogle Scholar5. Avraham S, Abu-Sharki S, Shofti R, Haas T, Korin B, Kalfon R, Friedman T, Shiran A, Saliba W, Shaked Y, et al.. Early cardiac remodeling promotes tumor growth and metastasis.Circulation. 2020; 142:670–683. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.046471LinkGoogle Scholar6. Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, Allgood PC, Kearins O, Tappenden N, O'Sullivan E, et al.. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival.Am J Epidemiol. 2008; 168:98–104. doi: 10.1093/aje/kwn120CrossrefMedlineGoogle Scholar7. Ma H, Wang J, Zhao X, Wu T, Huang Z, Chen D, Liu Y, Ouyang G. Periostin promotes colorectal tumorigenesis through integrin-FAK-Src pathway-mediated YAP/TAZ activation.Cell Rep. 2020; 30:793–806. doi: 10.1016/j.celrep.2019.12.075CrossrefMedlineGoogle Scholar8. González-González L, Alonso J. Periostin: a matricellular protein with multiple functions in cancer development and progression.Front Oncol. 2018; 8:225. doi: 10.3389/fonc.2018.00225CrossrefMedlineGoogle Scholar9. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J, Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy.Proc Natl Acad Sci U S A. 1991; 88:8277–8281. doi: 10.1073/pnas.88.18.8277CrossrefMedlineGoogle Scholar10. Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload.Histochem Cell Biol. 2009; 131:471–481. doi: 10.1007/s00418-008-0541-5CrossrefMedlineGoogle Scholar11. Baumgarten G, Knuefermann P, Kalra D, Gao F, Taffet GE, Michael L, Blackshear PJ, Carballo E, Sivasubramanian N, Mann DL. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart.Circulation. 2002; 105:2192–2197. doi: 10.1161/01.cir.0000015608.37608.18LinkGoogle Scholar12. Suetomi T, Miyamoto S, Brown JH. Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.Am J Physiol Heart Circ Physiol. 2019; 317:H877–H890. doi: 10.1152/ajpheart.00223.2019CrossrefMedlineGoogle Scholar13. Tanaka S, Saito Y, Kunisawa J, Kurashima Y, Wake T, Suzuki N, Shultz LD, Kiyono H, Ishikawa F. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice.J Immunol. 2012; 188:6145–6155. doi: 10.4049/jimmunol.1103660CrossrefMedlineGoogle Scholar14. Koelwyn GJ, Newman AC, Afonso MS, van Solingen C, Corr EM, Brown EJ, Albers KB, Yamaguchi N, Narke D, Schlegel M, et al.. Myocardial infarction accelerates breast cancer via innate immune reprogramming [published online July 13, 2020].Nat Med. doi: https://doi.org/10.1038/s41591-020-0964-7. https://www.nature.com/articles/s41591-020-0964-7Google Scholar15. Aboumsallem JP, Moslehi J, de Boer RA. Reverse cardio-oncology: cancer development in patients with cardiovascular disease.J Am Heart Assoc. 2020; 9:e013754. doi: 10.1161/JAHA.119.013754LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByFleming M, Xiao L, Jackson K, Beckman J, Barac A and Moslehi J (2021) Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors, Circulation Research, 128:12, (1973-1987), Online publication date: 11-Jun-2021.Related articlesEarly Cardiac Remodeling Promotes Tumor Growth and MetastasisShimrit Avraham, et al. Circulation. 2020;142:670-683 August 18, 2020Vol 142, Issue 7Article InformationMetrics Download: 3,187 © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.048655PMID: 32804565 Originally publishedAugust 17, 2020 KeywordsneoplasmsEditorialscardiologymodels, animalPDF download SubjectsCardiotoxicityCardio-OncologyAnimal Models of Human DiseaseMyocardial BiologyBiomarkers

Abstract:As the development of early detection and therapies advances in cancer patients, mortality rates attributed to cancer have declined. In the United States, there are approximately 15.5 million cancer survivors, and the number will grow to more than 20 million by 2026 (http://www.cancer.org/cancer/news/news/report-number-of-cancer-survivors-continues-to-grow). Unfortunately, the improved survival in cancer patients from cancer therapy is achieved at the expense of treatment-induced adverse effects with CVD being one of the most frequent side effects [Supplementary Table 1].[1] This may result from the direct cardiotoxicity of anticancer treatment or from the accelerated preexisting CVD or cardiovascular risk factors. CVD is now the second leading cause of long-term morbidity and mortality among cancer survivors.[234567]Supplementary Table 1: Incidence of common cardiovascular side effects associated with chemotherapy drugsThe presence of CVD may limit the treatment options for cancer. Here we share a case: A 60-year-old male patient with a 30-year history of smoking was diagnosed with non-ST-segment elevation myocardial infarction four years ago. Coronary angiography (CAG) showed 50% stenosis of the mid-left anterior descending (LAD) artery and 75% stenosis of the distal diagonal branch without percutaneous intervention. One year ago, he was diagnosed with squamous cell carcinoma of the left lung (cT3N2 MX) and treated with afatinib. Due to the tumor progression, he underwent chemotherapy of gemcitabine and cisplatin in place of afatinib. On the 7th day of the second chemotherapy cycle, the patient presented with sudden and persistent chest pain with subsequent electrocardiogram demonstrating ST-segment elevation myocardial infarction. CAG confirmed the occlusion in the proximal LAD for which percutaneous coronary intervention treatment was provided. Gemcitabine was discontinued in the subsequent chemotherapy for the considering that the acute myocardial infarction may induced by gemcitabine. Such a case is one of the many that we have encountered where cancer was complicated by cardiovascular disease (CVD). Cardiovascular toxicity induced by cancer treatment is a common and pressing issue for cardiologists and oncologists. To sustain survival improvement achieved using modern cancer therapies, the importance of CVD in cancer patients has been increasing recognized, leading to the emergence and development of the cross-disciplinary field of cardio-oncology. In 2000, the first onco-cardiology unit was established at the University of Texas MD Anderson Cancer Center, and in 2009, International Cardio-Oncology Society was established by the European Institute of Oncology.[8] The International Conference on Cancer and the Heart has been held in Texas every 2 years since 2010. Along with many publications from clinical and pathological observations or clinical trials, cardio-oncology specialists all over the world have been concentrating on their efforts in investigating epidemiologic burden, biomarkers and imaging for CVD prediction, and risk stratification and the effects of cardio-protective strategies. Just during 2016, four practice guidelines or consensus was published on the evaluation, prevention, and management of CVD in cancer survivors. These have set the foundation for this new discipline.[191011] Recently, an opinion paper on cardiovascular toxicity related to anticancer treatment from the working group on cardio-oncology of the Korean Society of Echocardiography provided more information.[12] As reported by the National Cancer Center of China, the incidence and mortality of cancer have increased significantly from 2000 to 2011 and there are now almost 10,000 new cancer diagnoses on average each day in China.[13] With the rapid development of cardio-oncology in Europe and US, it is increasingly being recognized among Chinese clinicians that it is critical to form a cross-disciplinary partnership in providing comprehensive CVD care for cancer survivors. In 2013, the Chinese Society of Clinical Oncology and the Chinese Medical Association published guidelines on the prevention and treatment of anthracycline-related cardiotoxicity and published updated version in 2017. In early 2016, a panel of 17 experts including cardiologists, oncologists, hematologists, cardiac imaging specialists, and basic research scientists initiated the China cardio-oncology network. The first workshop was held on June 5, 2016, in Dalian, China. Experts discussed the most appropriate approach to launch cardio-oncology in China. A second workshop swiftly followed on August 12, 2016, in Beijing, the group confirmed the concept and scope of the cardio-oncology program in China, which includes treatment-associated CVD in cancer patients, comorbidity of CVD and cancer, shared risk factors in cancer, and CVD and cardiac tumors. Cardiovascular toxicity from chemotherapy, radiation therapy, targeted drug therapy, and surgery-related adverse effects[141516] all contribute to the cardiovascular events in cancer patients. Age, preexisting CVD risk factors (smoking, obesity, sedentary habit, family history of premature CVD, etc.), specific chemotherapy agents and dosage, radiotherapy area, and dosage are common risk factors closely related to cardiovascular toxicity. According to the 2016 European Society of Cardiology (ESC) Position Paper on cancer treatments and cardiovascular toxicity, cardiovascular complications are classified into nine main categories: myocardial dysfunction and heart failure, coronary artery disease (CAD), valvular disease, arrhythmias, especially those induced by QT-prolonging drugs, arterial hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension, and pericardial complications.[1] An increasing body of evidence suggests that targeting modifiable risk factors, early prevention, and treatment can mitigate the degree of cardiotoxicity and early detection is increasingly important.[151617] For example, prophylactic use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) or beta blockers could prevent anthracycline/trastuzumab-induced cardiotoxicity in adult cancer populations. The above-mentioned ESC Position Paper guideline provides screening and evaluation recommendations or suggestions for every category. As illustrated in the case mentioned in the beginning of this article, acute myocardial infarction can be precipitated by targeted drug therapy and traditional chemotherapy in cancer patients with preexisting CAD. While cancer produces a hypercoagulable state, it also predisposes patients to bleeding, which limits options for medical and interventional therapies such as the use of antiplatelet drugs and anticoagulants. Similarly, when a thromboembolic event or atrial fibrillation occurs in cancer patients, it is difficult to balance the bleeding risk and provide the more appropriate anticoagulation strategies. Although the current guidelines offer some general recommendations, clinical trials are urgently needed, especially on the suitability of these practice guidelines from Europe for Chinese cancer patients. In recent years, as aging population becomes an increasing trend in China, a number of common risk factors presented in cancer and CVD patients, including obesity, diet, smoking, diabetes mellitus, and hyperlipidemia, become more prevalent.[1819] As an example, there is convincing evidence supporting the correlation between obesity and esophageal adenocarcinoma, pancreatic, liver, colorectal, postmenopausal breast, endometrial, and kidney cancer. Epidemiological data suggest that up to 20% of malignancies could be related to weight gain and obesity.[20] As a report by the American Diabetes Association in 2010, there is convincing evidence associating colorectal, breast, endometrial, liver, pancreatic, and bladder cancers with diabetes mellitus.[21] In addition, treating CVDs and CVD-related risk factors may affect the risk and prognosis of cancer. For example, ACEI showed an association with breast cancer recurrence;[22] aspirin reduced the risk of colorectal cancer by 24%;[23] prediagnostic statin use reduces the risk of lethal prostate cancer;[24] and statin use either before or after diagnosis of cancer was associated with improved cancer specific as well as overall survival.[25] The overlap of risk factors in CVD and cancer suggests that the two seemingly different diseases might share some common biological molecular mechanisms such as inflammation, oxidative stress, and reactive oxygen species. Controlling CVD risk factors can help reduce the risk of cancer. Further understanding of the delicate interaction between CVD and cancer may lead to better prevention, earlier detection, and safer treatment strategies. Cardiac tumors can be divided into primary and secondary cardiac tumors. A 20-year experience with review of 12,485 consecutive autopsies showed that their incidences are 0.056% and 1.23%, respectively. For secondary cardiac tumors, the common primary sources are carcinoma of the lung, breast, pancreatic, esophageal, liver, gastric and lymphoma, and leukemia.[26] Seventy-five percent of patients with cardiac tumors are benign.[27] Primary malignant cardiac tumors represented by sarcomas and non-Hodgkin lymphomas are rare and associated with a grave prognosis. Lestuzzi et al.[28] stressed the importance of the multidisciplinary approach and involvement of cardio-oncologists in making the diagnostic and treatment decisions. The prognosis may be improved by a careful planning of surgery and through the use of multimodality treatment including chemotherapy and radiation therapy. A strict follow-up protocol must be planned even following complete cure. After the workshops, the expert panel published a proposal to call attention to the cardio-oncology and strengthened physicians’ education through national medical meetings and online promotion and established international exchanges and cooperation. The first cardio-oncology clinic in China was established in the First Affiliated Hospital of Dalian Medical University in August 22, 2016, and a preliminary cardio-oncology consultation program was performed simultaneously [Figure 1]. Some cancer centers also set up cardiology department to provide CVD care for cancer patients after the cardio-oncology workshops.Figure 1: The cardio-oncology consultation program for cancer patients of the First Affiliated Hospital of Dalian Medical University. ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor antagonist; BNP: Brain natriuretic peptide; CAD: Coronary artery disease; CVD: Cardiovascular disease; cTnI: Cardiac troponin I; ECG: Electrocardiogram; HF: Heart failure; HTN: Hypertension; LVEF: Left ventricular ejection fraction.The First China Cardio-Oncology Conference entitled “Prevention, Early Intervention, Multidisciplinary Collaboration” was successfully held in Dalian on November 18–19, 2016. Meeting topics included the current status and future directions of cardio-oncology, overview of anticancer therapies and associated cardiotoxicity, establishment of cardio-oncology units in domestic hospitals, echocardiographic evaluation, cardiac tumors, basic research, and case presentations. It attracted over 300 attendees from around the country, indicating the increased clinician awareness on the educational initiatives and the importance of this new discipline. Subsequently, numerous cardio-oncology forums were set up in academic conferences on cardiovascular and oncology for communication and education. In addition, it is encouraging that the research work on cardio-oncology in China has achieved progression both in basic and clinical research. For example, further understanding on the relationship between end-stage carcinoma and acquired long QT syndrome might provide a new predictor of risk of all-cause mortality for cancer patients,[29] and we speculate that correction of the related risk factors will improve the prognosis of cancer patients. Animal experiments have explored potential specific protection measure against doxorubicin-induced myocardial dysfunction.[30] The booming development of cardio-oncology in China has beyond our expectation. Although the cardio-oncology is rapidly growing in China, there are few Chinese cardio-oncologists because of the complexity of cancer and anticancer therapy and insufficient communication between cardiology and oncology before the recognition of cardio-oncology as an established and recognized specialty. A cardio-oncologist should be a health-care provider who is focused on the prevention, early detection, and management and treatment of cardiac injury that may stem from cancer or cancer therapies.[31] To develop the discipline, we need to first establish a training system based on the experience from Europe and America. The training curriculum should be targeted to cardiologists and focused on cancer and anticancer treatments as well as the associated cardiotoxicity.[32] It is important to increase our collective understanding and ability to modify the interactions between cancer and cardiovascular health. The main focus of cardio-oncology is to improve the prognosis of cancer patients. The cardio-oncology specialty is at its infant stage in China. Currently, the lack of evidence to guide clinical decision-making and recommendations suitable for Chinese patients in cardio-oncology is a major challenge for health-care professionals. Several studies suggest that early detection of cardiovascular toxicity is possible through risk stratification before initiation of cancer therapy and periodic evaluation with physical examinations, echocardiography, magnetic resonance imaging, multigated acquisition scan, electrocardiogram, and biomarkers. ACEI/ARB and beta-blockers can reduce cancer therapy-related cardiac dysfunction and reduce mortality. The Society for Cardiovascular Angiography and Interventions recommends prechemotherapy cardioprotection. For patients with established CAD and without contraindications, adding or continuing ACEI and beta-blockers (preferably carvedilol or nebivolol) may provide additional cardioprotection. Based on the current experience, multicenter and multidiscipline association is optimal to create the clinical database and implement large prospective studies to develop the standard programs for CVD screening, prevention, treatment, and management. The mechanisms of cancer and anticancer treatment-related cardiovascular toxicity are not very well studied. Basic, translational, and clinical research is needed to explore the molecular pathways of the CV toxicity from cancer therapies and to improve the effective interventions. In summary, cardio-oncology is a new cross-discipline specialty with a focus on the cardiovascular health of cancer patients and cancer survivors. With the increasing recognition and the support of numerous cardiologists, oncologists, hematologists, cardiac imaging specialists, and basic research scientists, cardio-oncology has been steadily gaining attention in China. In addition to establishing multidiscipline training programs for cardiologists specializing in cardio-oncology, clinical and basic medical research will be urgently needed to provide clinical data and evidence-based approach in cardiovascular care unique to Chinese patients with cancer. Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

Current evidence regarding the cellular mechanisms associated with cancer progression due to cardiovascular diseases

Abstract 2007: Ischemic And Non-ischemic Cardiovascular Events Differentially Regulate Cross Disease Communication With Cancer

Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth

Crosstalk Between the Heart and Cancer

Understanding the impact of heart failure treatment on cancer growth

Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis

CVD phenotyping in oncologic disorders: cardio-miRNAs as a potential target to improve individual outcomes in revers cardio-oncology

Cardioprotection and Suppression of Fibrosis by Diverse Cancer and Non-Cancer Cell Lines in a Murine Model of Duchenne Muscular Dystrophy

Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: The paradigm of radiotherapy

Increased incidence risks of cardiovascular disease among cancer patients: Evidence from a population-based cohort study in China

Emergence, Development, and Future of Cardio-Oncology in China

New progress in elucidating the relationship between cancer therapy and cardiovascular toxicity

New Progress in Elucidating the Relationship Between Cancer Therapy and Cardiovascular Toxicity.

Cardiovascular health of patients with cancer: Challenges abound

Premature senescence and cardiovascular disease following cancer treatments: mechanistic insights

Emerging Roles of Microrna-208A in Cardiology and Reverse Cardio-Oncology

Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer

Effects of Breast Cancer Genes 1 and 2 on Cardiovascular Diseases

Calcium-sensing receptor and NF-κB pathways in TN breast cancer contribute to cancer-induced cardiomyocyte damage via activating neutrophil extracellular traps formation

Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review

Analysis of Epidemiological Characteristics of New Cardiovascular Diseases in Cancer Patients with Cardiovascular Disease